ATNM Actinium Pharmaceuticals, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1388320 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY130.6%
TTM EPS YoY130.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE55.2%
ROA23.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.20x
Accruals ratio76.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $90,000 | — |
| R&D expense | $21.12M | $30.05M |
| SG&A expense | $15.21M | $12.08M |
| Operating income | -$36.25M | -$42.12M |
| Pretax income | -$33.29M | -$38.24M |
| Net income | -$33.89M | -$38.24M |
| EBITDA | -$36.07M | -$41.92M |
| EPS (basic) | -1.09 | -1.27 |
| EPS (diluted) | -1.09 | -1.27 |
| Weighted avg. shares (diluted) | 31.20M | 30.07M |
| Balance sheet | ||
| Cash & equivalents | $48.00M | $73.23M |
| Current assets | $49.38M | $74.51M |
| PP&E, net | $295,000 | $364,000 |
| Total assets | $51.77M | $76.90M |
| Current liabilities | $7.97M | $8.15M |
| Total liabilities | $43.94M | $44.14M |
| Shareholders' equity | $7.83M | $32.76M |
| Shares outstanding | 31.20M | 31.20M |
| Cash flow statement | ||
| Operating cash flow | -$24.58M | -$33.07M |
| Capital expenditure | $104,000 | $11,000 |
| Free cash flow | -$24.68M | -$33.08M |
| Investing cash flow | -$104,000 | -$11,000 |
| Financing cash flow | -$217,000 | $29.32M |
| Depreciation & amortization | $173,000 | $197,000 |
| Stock-based compensation | $9.19M | $5.29M |
Free plan shows the latest 2 periods; Pro shows all 25 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.